A recent study published in the Journal of Allergy and Clinical Immunology suggests that a soluble form of the immunoglobulin E (IgE) receptor, sFcεRI, could serve as both a biomarker of disease severity and a natural “brake” against severe allergic reactions in patients with systemic mastocytosis (SM).
Mastocytosis is characterized by the abnormal accumulation of mast cells in various organs. When these cells are activated by IgE, an antibody involved in allergic reactions, they release inflammatory mediators such as histamine.
Researchers noted that while elevated levels of sFcεRI are more common in advanced subtypes of SM, the data point to a potential protective mechanism: sFcεRI might help dampen life-threatening anaphylactic symptoms by intercepting IgE signals before they trigger an allergic reaction.
Read more about SM signs and symptoms
The study analyzed 189 serum samples from 114 patients with mastocytosis and 15 healthy individuals. The researchers observed that, while sFcεRI levels varied significantly among individuals, including healthy controls, there was a clear trend associated with disease severity. Patients with advanced SM generally exhibited higher median protein levels than those with non-advanced forms. However, the study also highlighted high individual variations, noting that values can fluctuate significantly even within the same disease subtype.
The study demonstrated that patients with very high sFcεRI levels (>20 ng/mL) were less likely to experience vascular instability (a sudden, dangerous drop in blood pressure) or severe headaches. This supports the hypothesis that the body may produce sFcεRI to counteract severe IgE-dependent symptoms.
In laboratory tests, sFcεRI was also shown to inhibit the growth of neoplastic (cancerous) mast cells and to enhance the effects of KIT-targeting drugs such as midostaurin and avapritinib.
“These data suggest that sFcεRI serves as a biologically relevant feedback regulator,” the authors noted, indicating that it could eventually lead to new therapeutic strategies. However, the researchers cautioned that sFcεRI is not a universal prognostic marker, as some patients with highly aggressive mast cell leukemia showed either normal or low levels of the protein.
Sign up here to get the latest news, perspectives, and information about SM sent directly to your inbox. Registration is free and only takes a minute.
